EP4122472B1 - Wässrige zusammensetzung zur verwendung bei der behandlung von verdauungsstörungen bei tieren - Google Patents

Wässrige zusammensetzung zur verwendung bei der behandlung von verdauungsstörungen bei tieren Download PDF

Info

Publication number
EP4122472B1
EP4122472B1 EP22185685.9A EP22185685A EP4122472B1 EP 4122472 B1 EP4122472 B1 EP 4122472B1 EP 22185685 A EP22185685 A EP 22185685A EP 4122472 B1 EP4122472 B1 EP 4122472B1
Authority
EP
European Patent Office
Prior art keywords
composition
weight
mpa
activated carbon
poids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP22185685.9A
Other languages
English (en)
French (fr)
Other versions
EP4122472A1 (de
EP4122472C0 (de
Inventor
Anne CHAUDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domes Pharma SA
Original Assignee
Domes Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domes Pharma SA filed Critical Domes Pharma SA
Publication of EP4122472A1 publication Critical patent/EP4122472A1/de
Application granted granted Critical
Publication of EP4122472C0 publication Critical patent/EP4122472C0/de
Publication of EP4122472B1 publication Critical patent/EP4122472B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention relates to an aqueous composition and to its use in the treatment of digestive disorders, in particular oral poisoning, in animals.
  • the adsorbent power is usually measured on the raw material, i.e. activated carbon alone in particular.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (10)

  1. Zusammensetzung, dadurch gekennzeichnet, dass sie, bezogen auf das Gesamtgewicht der Zusammensetzung, umfasst
    - 20 bis 35 Gewichtsprozent Aktivkohle,
    - 4 bis 7 Gewichtsprozent Natriumsulfat,
    - 15 bis 25 Gewichtsprozent Glycerin,
    - 0,15 bis 0,40 Gewichtsprozent Xanthan-Gummi,
    - 30 bis 60 Gewichtsprozent Wasser.
  2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass sie zusätzlich 0,15 bis 0,60 Gewichtsprozent Carboxymethylcellulose bezogen auf das Gesamtgewicht der Zusammensetzung umfasst.
  3. Zusammensetzung nach Anspruch 2, dadurch gekennzeichnet, dass sie 0,25 bis 0,45 Gewichtsprozent Carboxymethylcellulose, bevorzugt 0,30 bis 0,45 Gewichtsprozent bezogen auf das Gesamtgewicht der Zusammensetzung umfasst.
  4. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass sie in flüssiger Form vorliegt und eine Viskosität bei 20 °C zwischen 50 mPa.s und 500 mPa.s, bevorzugt zwischen 50 mPa.s und 200 mPa.s, besonders bevorzugt zwischen 150 mPa.s und 250 mPa.s und ganz besonders bevorzugt zwischen 180 mPa.s und 200 mPa.s aufweist.
  5. Zusammensetzung nach Anspruch 2 oder 3, dadurch gekennzeichnet, dass sie in Form einer Paste vorliegt und eine Viskosität bei 20 °C zwischen 4000 mPa.s und 15000 mPa.s, bevorzugt zwischen 5000 mPa.s und 10000 mPa.s und besonders bevorzugt zwischen 6000 mPa.s und 7000 mPa.s aufweist.
  6. Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass das Massenverhältnis zwischen Aktivkohle und Natriumsulfat zwischen 70:30 und 85:15 liegt.
  7. Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass sie zusätzlich Kaliumsorbat als antimikrobielles Konservierungsmittel in einer Menge von 0,5 bis 2 Gewichtsprozent, bevorzugt 0,5 bis 1,5 Gewichtsprozent bezogen auf das Gesamtgewicht der Zusammensetzung umfasst.
  8. Zusammensetzung nach einem der vorstehenden Ansprüche zur Verwendung bei der Behandlung von Verdauungsstörungen bei Tieren durch orale Verabreichung.
  9. Zusammensetzung zur Verwendung nach Anspruch 8, dadurch gekennzeichnet, dass es sich bei der Verdauungsstörung um eine Vergiftung durch orale Aufnahme handelt.
  10. Vorrichtung zur oralen Verabreichung einer Zusammensetzung an ein Tier, dadurch gekennzeichnet, dass sie ein Behältnis umfasst, das eine Zusammensetzung nach einem der Ansprüche 1 bis 7 enthält.
EP22185685.9A 2021-07-19 2022-07-19 Wässrige zusammensetzung zur verwendung bei der behandlung von verdauungsstörungen bei tieren Active EP4122472B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR2107762A FR3125219B1 (fr) 2021-07-19 2021-07-19 Composition aqueuse utilisee dans le traitement des troubles digestifs chez les animaux

Publications (3)

Publication Number Publication Date
EP4122472A1 EP4122472A1 (de) 2023-01-25
EP4122472C0 EP4122472C0 (de) 2025-03-05
EP4122472B1 true EP4122472B1 (de) 2025-03-05

Family

ID=77821883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22185685.9A Active EP4122472B1 (de) 2021-07-19 2022-07-19 Wässrige zusammensetzung zur verwendung bei der behandlung von verdauungsstörungen bei tieren

Country Status (4)

Country Link
EP (1) EP4122472B1 (de)
CA (1) CA3168276A1 (de)
ES (1) ES3015738T3 (de)
FR (1) FR3125219B1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917821A (en) * 1973-10-23 1975-11-04 Milton Manes Palatable activated carbon
US4122169A (en) 1976-04-27 1978-10-24 Geils John H Activated carbon-sorbital composition and adsorption-expulsion treatment therewith

Also Published As

Publication number Publication date
EP4122472A1 (de) 2023-01-25
FR3125219A1 (fr) 2023-01-20
FR3125219B1 (fr) 2024-10-18
EP4122472C0 (de) 2025-03-05
CA3168276A1 (fr) 2023-01-19
ES3015738T3 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
EP1492531B3 (de) Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
KR20140088234A (ko) 안정성이 증진된 페닐에프린 액상 조성물
WO1998005314A1 (fr) Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
WO2003084518A2 (fr) Suspension orale de microcapsules de principes actifs
US3917821A (en) Palatable activated carbon
FR2946882A1 (fr) Suspension veterinaire gelifiee de fer
JP4393192B2 (ja) リバビリンシロップ処方物
EP4122472A1 (de) Wässrige zusammensetzung zur verwendung bei der behandlung von verdauungsstörungen bei tieren
FR2732217A1 (fr) Forme d'administration solide a usage oral
EP2745839B1 (de) Pharmazeutische Zusammensetzung in Form einer Suspension zur Einnahme, die eine flavonoidhaltige Fraktion und Xanthangummi enthält
WO2019158873A1 (fr) Composition multiusage de torasemide
FR2720944A1 (fr) Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie.
FR2753097A1 (fr) Gel aqueux ou hydroalcoolique extemporane a viscosite controlee
WO2009083520A2 (fr) Compositions orales liquides de florfenicol diluables dans l'eau de boisson
EP2237769B1 (de) Selbstemulgierbare flüssige florfenicolzusammensetzung als zusatz für das trinkwasser von nutztieren
EP3119475A1 (de) Verwendung einer veterinärmedizinischen zusammensetzung auf der basis von torasemid zur niedrigdosierten verabreichung
EP4122473A1 (de) Zusammensetzung auf der basis von aktivkohle zur verwendung bei der behandlung von verdauungsstörungen bei tieren
WO2008099068A2 (fr) Composition liquide anhydre destinee a etre incorporee a l'eau de boisson des animaux d'elevage
FR3000400B1 (fr) Suspension huileuse de metronidazole
CH650150A5 (fr) Composition pharmaceutique renfermant du cromoglycate de sodium.
WO2021069836A1 (fr) Masquage du goût de l'isosorbide
GB2564515A (en) Pharmaceutical composition and a method for manufacturing the same
BE461911A (de)
FR3016520A3 (fr) Composition nutritionnelle a base d'acide hyaluronique pour la nutrition des articulations
RU2008139472A (ru) Антисептическая фармацевтическая композиция, способ ее получения и применение

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230724

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231220

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20241120

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602022011343

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20250305

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250606

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 4

Effective date: 20250731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250811

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250705

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260114

26N No opposition filed

Effective date: 20251208

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250731